Skip to content

CogEcig: Cognitive Functioning and Electronic Cigarette

Electronic Cigarette and Cognitive Functioning: (CogEcig)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01735487
Acronym
CogEcig
Enrollment
20
Registered
2012-11-28
Start date
2012-09-30
Completion date
2012-12-31
Last updated
2012-12-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tobacco Abuse Smoke

Brief summary

The aim of the present study is to compare cognitive scores (attention, executive function and working memory) of different e-Cigarette strength with usual cigarettes.

Detailed description

The study is randomised cross-over trial designed to compare: 1) Cognitive performances levels for four different e-Cigarette strength. Participants will be requested to abstain from smoking and alcohol from 20:00 on the night before each study day and from food and caffeine for at least 1 h before the session. On arrival at the study centre, carbon monoxide (CO) will be measured in participants' expired breath. If CO will be \>15 parts per million (ppm), the assigned study treatment will be allocated; however, if CO was \>15 ppm or they will report smoking in the previous 12 h, participants will be rescheduled wherever possible to a subsequent session. On the first study day, participants will be randomised to use one of five ordered conditions: Electronic Nicotine Delivery Device (ENDD) (fourth generation) containing nicotine 2,4%; Electronic Nicotine Delivery Device (ENDD (second generation) containing nicotine 7,4 mg; Electronic Nicotine Delivery Device (ENDD containing nicotine 9 mg; Electronic Nicotine Delivery Device (ENDD nicotine free; their usual cigarette. Additionally participants will be trained to use an electronic cigarette. The following tests will be completed at the each visits: Continuous Performance Test - AX version (CPT-AX), Wisconsin card sorting test( WCST), Working memory test (N-BACK).

Interventions

Smoke, 15 puff of, Own Brand cigarettes;

Smoke, 25 puff, of electronic cigarette one high 2,4% nicotine

Smoke, 15 puff, of Categoria electronic cigarette 7,4 mg nicotine

smoke, 15 puff, of electronic cigarette nicotine free

OTHEREgo 9mg

smoke, 15 puff, of electronic cigarette Ego 9 mg

Sponsors

Universita degli Studi di Catania
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* 20 regular smokers (smoking ≥ 15 factory-made cigarettes per day for at least the past 10 years and not currently attempting to quit smoking or wishing to do so in the next 30 days, CO \> 10 parts per million ) will be recruited from the local Hospital staff in Catania, Italy.

Exclusion criteria

* people who reported recent myocardial infarction, angina pectoris or other serious medical conditions (diabetes mellitus, severe allergies, poorly controlled asthma or other airways disease, poorly controlled psychiatric disorders or current chemical dependence other than nicotine) and * pregnancy, * breastfeeding, * blood pressure \> 180 mm Hg systolic and/or 100 mm Hg diastolic, * weight \< 45 or \> 120 kg, or * current use of any other smoking cessation medications

Design outcomes

Primary

MeasureTime frameDescription
Cognitive Performances35 minutesCompare cognitive performances in subjects who smoke Categoria electronic cigarettes labelled Original 7,4 mg nicotine , Categoria electronic cigarettes labelled One 2,4% nicotine, Categoria electronic cigarettes labelled Mint nicotine free, electronic cigarettes labelled Ego 9 mg nicotine with usual cigarettes.

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 27, 2026